menu

CME: Rethinking Approaches to Biliary Tract Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Rethinking Approaches to Biliary Tract Carcinoma

Program Information
Recommended
Rethinking Approaches to Biliary Tract Carcinoma
RestartResume
Thanks to exciting clinical trials currently underway, we may soon have answers to help us address unmet needs in biliary tract carcinoma care.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There’s no denying that biliary tract carcinoma (BTC) presents formidable diagnostic and treatment challenges. That’s why it’s so important for practitioners to stay up to date on the pathophysiology of BTC, as well as current—and even future—first- and second-line treatments. And here to break all those options down for us are Drs. Mitesh Borad and Milind Javle.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Mitesh J. Borad, MD
    Director, Liver and Biliary Cancer Research Program
    Mayo Clinic
    Phoenix, AZ

    Dr. Borad has disclosed consulting fees for Merck, and contracted research for Agios, AstraZeneca, Basil Pharmaceuticals, Celgene, EMD Serono, Halozyme, Inc., Incyte, Que Oncology, Senhwa Biosciences, and Taiho Oncology.

    Milind Javle, MD
    The University of Texas MD Anderson Cancer Center
    Department of Gastrointestinal Medical OncologyDivision of Cancer Medicine
    Houston, TX

    Dr. Javle has disclosed he receives honoraria from Merck, Seattle Genetics, and Taiho; research and grant funding from Arqule, Lilly, Meclun, Novartis, and QED; and is a consultant for EDO, More Health, and Origimed. 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the pathophysiology and burden of disease of biliary tract carcinomas (BTC).
    • Analyze current therapeutic approaches to BTC, especially as related to late stage disease and unacceptably poor patient outcomes.
  • Target Audience

    This activity is designed to meet the educational needs of practicing Oncologists, Medical Oncologists and Hematologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Programs 8/20/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.